Schizophrenia Research
Volume 93, Issue 1 , Pages 90-98 , July 2007

Weight gain in newly diagnosed first-episode psychosis patients and healthy comparisons: One-year analysis

  • Martin Strassnig

      Affiliations

    • Western Psychiatric Institute and Clinic, University of Pittsburgh Medical Center, 3811 O'Hara Street, Pittsburgh, PA 15213, United States
    • ,
  • Jean Miewald

      Affiliations

    • Western Psychiatric Institute and Clinic, University of Pittsburgh Medical Center, 3811 O'Hara Street, Pittsburgh, PA 15213, United States
    • ,
  • Matcheri Keshavan

      Affiliations

    • Department of Psychiatry, Wayne State University, Detroit, MI, United States
    • ,
  • Rohan Ganguli

      Affiliations

    • Western Psychiatric Institute and Clinic, University of Pittsburgh Medical Center, 3811 O'Hara Street, Pittsburgh, PA 15213, United States
    • Corresponding Author InformationCorresponding author. Tel.: +1 412 246 5006; fax: +1 412 246 5007.

Received 20 November 2006 ,Revised 6 February 2007 ,Accepted 12 February 2007.

References 

  1. Addington J, Mansley C, Addington D. Weight gain in first-episode psychosis. Can. J. Psychiatry. 2003;48(4):272–276
  2. Allison DB, Fontaine KR, Heo M, Mentore JL, Cappelleri JC, Chandler LP, et al. The distribution of body mass index among individuals with and without schizophrenia. J. Clin. Psychiatry. 1999;60(4):215–220
  3. Andreasen NC. The Scale for the Assessment of Negative Symptoms (SANS): conceptual and theoretical foundations. Br. J. Psychiatry Suppl. 1989;49–58
  4. Andreasen NC. Methods for assessing positive and negative symptoms. Mod. Probl. Pharmacopsychiatry. 1990;24:73–88
  5. Ball K, Crawford D. Socioeconomic status and weight change in adults: a review. Soc. Sci. Med. 2005;60(9):1987–2010
  6. Brar JS, Ganguli R, Pandina G, Turkoz I, Berry S, Mahmoud R. Effects of behavioral therapy on weight loss in overweight and obese patients with schizophrenia or schizoaffective disorder. J. Clin. Psychiatry. 2005;66(2):205–212
  7. Brown S, Birtwistle J, Roe L, Thompson C. The unhealthy lifestyle of people with schizophrenia. Psychol. Med. 1999;29(3):697–701
  8. Coldham EL, Addington J, Addington D. Medication adherence of individuals with a first episode psychosis. Acta Psychiatr. Scand. 2002;106:286–290
  9. Daumit GL, Crum RM, Guallar E, Powe NR, Primm AB, Steinwachs DM, et al. Outpatient prescriptions for atypical antipsychotics for African Americans, Hispanics and Whites in the United States. Arch. Gen. Psychiatry. 2003;60:121–128
  10. Faulkner G, Soundy AA, Lloyd K. Schizophrenia and weight management: a systematic review of interventions to control weight. Acta Psychiatr. Scand. 2003;108:324–332
  11. First MB, Spitzer RL, Gibbon M, Williams JBW. Structured Clinical Interview for DSM-IV Axis I Disorders, Clinician Version (SCID-CV). Washington DC: American Psychiatric Press; 1996;
  12. Ganguli R, Strassnig M. Are older antipsychotic drugs obsolete. Br. Med. J. 2006;332:1346–1347
  13. Ganguli R. Weight gain associated with antipsychotics. J. Clin. Psychiatry. 1999;60(suppl 21):20–24
  14. Ganguli R, Brar JS, Ayrton Z. Weight gain over 4 months in schizophrenia patients: a comparison of olanzapine and risperidone. Schizophr. Res. 2001;49:261–267
  15. Ganguli R, Brar JS. Prevention of Weight gain, by behavioral interventions, in patients starting novel antipsychotics. Schizophr. Bull. 2005;31(2):561–562
  16. Hamilton M. A rating scale for depression. J. Neurol. Neurosurg. Psychiatry. 1960;23:56–62
  17. Helgason L. Twenty years' follow up of first psychiatric presentation for schizophrenia: what could have been prevented?. Acta Psychiatr. Scand. 1990;81:231–235
  18. Henderson DC, Cagliero E, Gray C, Nasrallah RA, Hayden DL, Schoenfeld DA, et al. Clozapine, diabetes mellitus, weight gain, and lipid abnormalities: A five-year naturalistic study. Am. J. Psychiatry. 2000;157(6):975–981
  19. Hollingshead AB. Four Factor Index of Social Status. In: CT: New Haven; 1975;p. 1–22
  20. Homel P, Casey D, Allison DB. Changes in body mass index for individuals with and without schizophrenia, 1987–1996. Schizophr. Res. 2002;55(3):277–284
  21. Kelly DL, Conley RR, Carpenter WT. First-episode schizophrenia. A focus on pharmacological treatment and safety considerations. Drugs. 2005;65(8):1113–1138
  22. Johnson DB, Gerstein DE, Evans AE, Woodward-Lopez G. Preventing obesity: a life cycle perspective. J. Am. Diet. Assoc. 2006;106(1):97–102
  23. Kinon BJ, Basson BR, Gilmore JA, Tollefson GD. Long-term olanzapine treatment: weight change and weight-related health factors in schizophrenia. J. Clin. Psychiatry. 2001;62(2):92–100
  24. Lieberman JA. Atypical antipsychotic drugs as a first-line treatment of schizophrenia. J. Clin. Psychiatry. 1996;57(suppl 11):68–71
  25. Lieberman JA, Sheitman B, Chakos M, Robinson D, Schooler N, Keith S. The development of treatment resistance in patients with schizophrenia: a clinical and pathophysiological perspective. J. Clin. Psychopharmacol. 1998;18:S20–S24
  26. Lieberman JA, Phillips M, Gu H, Stroup S, Zhang P, Kong L, et al. Atypical and conventional antipsychotic drugs in treatment-naïve first-episode schizophrenia: a 52-week randomized trial of clozapine vs. chlorpromazine. Neuropsychopharmacology. 2003;28(5):995–1003
  27. Marder SR, Essock SM, Miller AL, Buchanan RW, Casey DE, Davis J, et al. Physical health monitoring of patient with schizophrenia. Am. J. Psychiatry. 2004;161(8):1334–1349
  28. McEvoy JP, Hogarty GE, Steingard S. Optimal dose of neuroleptic in acute schizophrenia. Arch. Gen. Psychiatry. 1991;48:739–745
  29. McEvoy JP, Meyer JM, Goff DC, Nasrallah HA, Davis SM, Sullivan L, et al. Prevalence of the metabolic syndrome in patients with schizophrenia: baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III. Schizophr. Res. 2005;80:19–32
  30. Meyer JM, Nasrallah HA, McEvoy JP, Goff DC, Davis SM, Chakos M, et al. The Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Schizophrenia Trial: clinical comparison of subgroups with and without the metabolic syndrome. Schizophr. Res. 2005;80:9–18
  31. Nakayama KM. Body weight induced by a newer antipsychotic agent reversed as negative symptoms improved. Acta Psychiatr. Scand. 2005;112:75–77
  32. National Task Force on the Prevention and Treatment of Obesity . Overweight, obesity and health risk. Arch. Intern. Med. 2000;160(7):898–904
  33. Osby U, Correia N, Brandt L, Ekbom A, Sparen P. Mortality and causes of death in schizophrenia in Stockholm County, Sweden. Schizophr. Res. 2000;45(1–2):21–28
  34. Poirier P, Giles TD, Bray GA, Hong Y, Stern JS, Pi-Sunyer FX, et al. Arterioscler. Thromb. Vasc. Biol. 2006;26(5):968–976
  35. Ratzoni G, Gothelf D, Brand-Gothelf A, Reidman J, Kikinzon L, Gal G, et al. Weight gain associated with olanzapine and risperidone in adolescent patients: a comparative prospective study. J. Am. Acad. Child. Adolesc. Psychiatry. 2002;41(3):337–343
  36. Robinson D, Woerner MG, Alvir JM, Bilder RM, Hinrichsen GA, Lieberman JA. Predictors of relapse following response from a first episode of schizophrenia or schizoaffective disorder. Arch. Gen. Psychiatry. 1999;56:241–247
  37. Russell JM, Mackell JA. Bodyweight gain associated with atypical antipsychotics: epidemiology and therapeutic implications. CNS Drugs. 2001;15(7):537–551
  38. Ryan MC, Thakore JH. Physical consequences of schizophrenia and its treatment: the metabolic syndrome. Life Sci. 2002;71(3):239–257
  39. Strassnig M, Brar JS, Ganguli R. Nutritional assessment of patients with schizophrenia: a preliminary study. Schizophr. Bull. 2003;29(2):393–397
  40. Strassnig M, Brar JS, Ganguli R. Body mass index and quality of life in community-dwelling patients with schizophrenia. Schizophr. Res. 2003;62(1–2):73–76
  41. Strassnig M, Brar JS, Ganguli R. Self-reported body weight perception and dieting practices in community-dwelling patients with schizophrenia. Schizophr. Res. 2005;75(2–3):425–432
  42. Thakore JH. Metabolic disturbance in first-episode schizophrenia. Br. J. Psychiatry. 2004;184(suppl 47):s76–s79
  43. Van Mastrigt S, Addington J, Addington D. Substance misuse at presentation to an early psychosis program. Soc. Psychiatry Psychiatr. Epidemiol. 2004;39:69–72
  44. Weiden P, Mackell J. Differing side effect burden with newer antipsychotics. Eur. Neuropsychopharmacol. 1999;9(suppl 5):S266
  45. Weiss R, Dziura J, Burgert TS, Tamborlane WV, Taksali SE, Yeckel CW, et al. Obesity and the metabolic syndrome in children and adolescents. N. Engl. J. Med. 2004;350(23):2362–2374
  46. Yan LL, Daviglus ML, Liu K, Stamler J, Wang R, Pirzada A, et al. Midlife body mass index and hospitalization and mortality in older age. JAMA. 2006;295:190–198
  47. Zipursky RB, Gu H, Green AI, Perkins DO, Tohen MF, McEvoy JP, et al. Course and predictors of weight gain in people with first-episode psychosis treated with olanzapine or haloperidol. Br. J. Psychiatry. 2005;187:537–543

PII: S0920-9964(07)00099-0

doi: 10.1016/j.schres.2007.02.024

Schizophrenia Research
Volume 93, Issue 1 , Pages 90-98 , July 2007

Article Tools

* Image Usage & Resolution